Clinical Trial Update: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on SOM230 (IGF-I action inhibitor) for breast cancer chemoprevention in Ductal Carcinoma In Situ; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: NYU Langone Health | Conditions: Ductal Carcinoma in Situ | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-12-27